Frankfurt
15.05.25 | 09:15
0,207 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2025 | 138 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 14, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 14 May 2025, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2025 | 190 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - March 2025 | 61 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - March 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"The... ► Artikel lesen | |
| 09.04. | Notice to Annual General Meeting in AlzeCure Pharma AB | 264 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 9, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the... ► Artikel lesen | |
| 07.04. | AlzeCure Pharma: New Data Bolstering the Anti-inflammatory Effect of NeuroRestore ACD856 Presented at Alzheimer's Conference | 264 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 7, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 03.04. | AlzeCure Pharma publishes its Annual Report for 2024 | 236 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 3, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.04. | AlzeCure Pharma: New Scientific Article in Nature Linking the Potential use of NeuroRestore ACD856 for the Treament of Obesity | 242 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 01.04. | AlzeCure Pharma to present at Redeye Theme: Alzheimer & Parkinsons on April 8 | 203 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 1, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.02. | AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2024 | 640 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 27, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January... ► Artikel lesen | |
| 24.02. | AlzeCure Pharma: New Article Showing the Unique Mechanism of Action Behind Alzstatin as an Alzheimer's Treatment | 270 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 24, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) ), a pharmaceutical company that develops candidate drugs for... ► Artikel lesen | |
| 17.02. | AlzeCure Pharma: AlzeCure Receives EU Grant for Phase 2 Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease | 288 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESS Newswire / February 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for... ► Artikel lesen | |
| 21.01. | AlzeCure Pharma: AlzeCure Receives Abstract Acceptance at Alzheimer's Congress AD/PD 2025 on NeuroRestore ACD856 | 341 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / January 21, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.11.24 | AlzeCure Pharma: AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm | 340 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for... ► Artikel lesen | |
| 26.11.24 | AlzeCure Pharma to Present at Redeye Life Science Day on December 3 | 296 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 20.11.24 | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm | 406 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 11.11.24 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2024 | 723 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September... ► Artikel lesen | |
| 30.10.24 | AlzeCure Pharma: AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD | 484 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 28.10.24 | AlzeCure Pharma: AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis | 283 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 24.10.24 | AlzeCure Pharma: AlzeCure to Present at the International Partnering Conference Bioscience 2024 on November 7 | 390 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 24, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 17.10.24 | AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day | 300 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 17, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 386,65 | +2,57 % | VERTEX PHARMACEUTICALS INC / MA - 8-K, Current Report | ||
| VIATRIS | 7,828 | +4,01 % | Viatris-Aktie mit Kursverlusten (7,55567 €) | Die Aktie von Viatris notiert am Mittwoch etwas leichter. Der jüngste Kurs betrug 8,47 US-Dollar. Heute hat sich am US-amerikanischen Aktienmarkt die Viatris-Aktie zwischenzeitlich um 3,64 Prozent verbilligt.... ► Artikel lesen | |
| OPKO HEALTH | 1,148 | +1,34 % | Entera Bio Ltd.: OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders | MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies... ► Artikel lesen | |
| JAGUAR HEALTH | 5,460 | -9,45 % | Jaguar Health, Inc.: Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates | Click here to registerCompany plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025 SAN FRANCISCO, CA / ACCESS Newswire / May 14, 2025 / Jaguar Health,... ► Artikel lesen | |
| ALTIMMUNE | 5,134 | +0,47 % | Piper Sandler maintains Altimmune stock with $25 target | ||
| SELLAS LIFE SCIENCES | 1,436 | +5,74 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML | NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 6,958 | -1,08 % | Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance | ||
| KIORA PHARMACEUTICALS | 3,020 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 | Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an update... ► Artikel lesen | |
| LIPOCINE | 3,730 | +11,34 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 | SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| PHOTOCURE | 4,195 | -1,41 % | Photocure ASA: Results for the first quarter of 2025 | OSLO, Norway, May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million)... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,114 | +4,95 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 25,150 | 0,00 % | Eurobio Scientific: 2024 annual results | 2024 ANNUAL RESULTS Growth of core business and strategic execution Revenue up 19% to €154 million Organic growth at +9%Proprietary products account for a stable 31% of group revenueInternational... ► Artikel lesen | |
| MEDICURE | 0,590 | 0,00 % | Medicure, Inc.: Medicure to Present Financial Results on April 29, 2025 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2024 | WINNIPEG, MB / ACCESS Newswire / April 22, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| MERCK KGAA | 115,40 | -6,82 % | BARCLAYS stuft MERCK KGAA auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Merck KGaA von 195 auf 160 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. Der nun verantwortliche... ► Artikel lesen | |
| BAYER | 22,865 | +3,13 % | Bayer-Aktie: Kurs klettert leicht (23,995 €) | An der deutschen Börse liegt das Wertpapier von Bayer aktuell im Plus. Die Aktie notiert gegenwärtig bei 24,00 Euro. Am Aktienmarkt liegt die Aktie von Bayer zur Stunde im Plus. Das Wertpapier legte... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,207 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.